The three-year study followed 3,508 patients with stage I through III colon or rectal cancer who had undergone surgery.

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Portuguese researchers have discovered that a type of white blood cell that can identify and kill tumour cells could be the key to a new immunotherapy against colorectal cancer, the most common type ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

The first patient with locally advanced rectal cancer has been enrolled in the FORTRESS study which is evaluating the ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

NIH researchers discovered that a new form of personalized cancer immunotherapy dramatically improved the treatment’s ...

US pharma major Bristol Myers Squibb has received full approval from the US Food and Drug Administration for the use of ...

A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable "cytokine factory" ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

At the core of AI’s value in cancer care is its performance in early detection and diagnostic support, where deep learning ...

A team of researchers from the Rice Biotech Launch Pad at Rice University in Houston developed the implantable “cytokine ...